Global Research PartnershipsCreate free account
Industry Collaboration Index

Industry Collaboration Index 2026 · University profile

Tianjin Medical University

China · Asia-Pacific

#741World rank of 1,038
37.1ICI scoreout of 100
#115National rank, of 169 in China
#231Regional rank, of 343 in Asia-Pacific
348Verified industry works, 2021 to 2025
161Company groups worked with (49 on two or more works)

Tianjin Medical University is ranked #741 of 1,038. Its strongest pillar is durability (68): 12 of its company groups are sustained partners (five or more joint works in three or more of the five years). It is held back most by co-creation (15): 348 verified industry works against about 701 expected for its mix of fields; and by scale (39): a network of 49 company groups on two or more joint works.

Research Collaboration Index 2026: #753 of 1,195 · View the RCI profile →

Why this position

Four pillars, as percentiles

Co-creation30% of the score
15

How often it co-authors with companies, compared with what its own mix of research fields would predict; size makes no difference. 348 verified works against about 701 expected for its fields (0.50 times the expected rate).

Durability20% of the score
68

How much of its industry work sits in sustained partnerships with the same company group. 12 sustained partnerships: five or more joint works in three or more of the five years.

Scale30% of the score
39

The size of its industry network: company groups on two or more works, sustained partnerships, and its place in the worldwide network of universities and companies. 49 company groups on two or more joint works; 12 sustained partnerships.

Breadth20% of the score
36

How varied its partners are, judged by each company's main research field. Measured across the main research fields of all the company groups it worked with.

Each pillar is a percentile among the 1,038 ranked universities: a value of 80 means a higher value than about 80 in every 100 of them. The ICI score (37.1) is the weighted average of the four percentiles. Rank 741 of 1,038 overall; 115 of 169 in China; 231 of 343 in Asia-Pacific. Standing bands: Platinum for ranks 1 to 100, Gold 101 to 300, Silver 301 to 600. How the index is built →

In numbers

The evidence behind the position

2.4%of its 14,745 research works in 2021 to 2025 were co-authored with a verified company
0.50Industry co-authorship rate: 0.50 times what its mix of research fields would predict (348 verified works; about 701 expected)
12sustained partnerships: the same company group on five or more joint works in three or more of the five years

In China

115 of 169 ranked universities in China

  1. #113 Huazhong Agricultural University world #735, score 37.5
  2. #114 Yunnan University world #740, score 37.1
  3. #115 Tianjin Medical University world #741, score 37.1
  4. #116 Guangzhou University of Chinese Medicine world #743, score 36.6
  5. #117 Hebei Medical University world #746, score 36.3

All ranked universities →   Asia-Pacific: 231 of 343 →

Where it works with industry

Sector strengths

Verified industry works by sector, with its position in each sector ranking. A university is ranked in a sector once it has at least 20 verified works there; sectors with fewer than 50 eligible universities are provisional.

Strongest sector positions

#307 of 638Pharmaceuticals and Therapeutics79 verified works in the sector
Pharmaceuticals and Therapeutics
79#307 of 638
Medical Technology and Digital Health
33.5#202 of 323
Biotechnology and Advanced Therapies
28.5#126 of 220
Artificial Intelligence
5under 20 works
Advanced Materials and Nanotechnology
3under 20 works
Climate, Environment and Sustainability
3under 20 works
Built Environment and Infrastructure
1.5under 20 works
Clean Energy Transition
1.5under 20 works
Advanced Manufacturing and Industry 4.0
1under 20 works
Agriculture and Food Technology
1under 20 works
Batteries and Energy Storage
0.5under 20 works
Robotics and Autonomous Systems
0.5ranking withheld (under 10 eligible)
Not in any of the 21 sectors
190counted in the overall index

158 of its 348 verified industry works fall within the 21 sectors. The rest have research topics that belong to no industry sector (basic science, for example) or are consortium papers with 100 or more authors, which the sector indices leave out; all of them count fully in the overall index.

Who it works with

Company partners, 2021 to 2025

Tianjin Medical University co-authored verified work with 161 company groups, consortium papers aside: 49 of them on two or more works, and 12 as sustained partners.

The largest 12 of its 161 company groups, by joint works

Company groupBased inCompany's main research fieldJoint worksYears with a joint work
Tianjin Institute of Pharmaceutical ResearchChinaMedicine43.55 of 5
SiemensGermanyEngineering385 of 5
PhilipsNetherlandsEngineering195 of 5
BGI GroupChinaBiochemistry, Genetics and Molecular Biology184 of 5
Beijing Biosis Healing Biological TechnologyChinaNot recorded185 of 5
Siemens HealthineersGermanyMedicine165 of 5
Jiangsu Hengrui MedicineChinaMedicine12.54 of 5
SanofiFranceMedicine84 of 5
SinopecSTATE-OWNEDChinaEngineering64 of 5
AbbVieUnited StatesMedicine54 of 5
Beijing Chemical Industry Research InstituteSTATE-OWNEDChinaMaterials Science54 of 5

1 further partner group is not named here because the open record gives an address, a person's name or other text in place of an organisation's name; its joint works still count in every figure on this page.

A company group brings together a company's subsidiaries and research labs under one name. A work counts half when its only company author also holds a post at this university. Consortium papers with 100 or more authors are left out of this table.

Examples of its work with industry

Most-cited verified joint works

Its most-cited verified works with 30 or fewer authors, leaving out guidelines and consensus statements. Citation counts are those of the open scholarly record at harvest. Each title links to the work.

Over time

Verified industry works by year

47.52021
722022
62.52023
712024
952025

2025 is not yet complete: papers published late in the year are still being added to the open record, and coverage may not be equally complete for every university, so compare years with care. A work counts half when its only company author also holds a post at the university, so some totals end in .5.

Clinical trials (reported, not scored)

39 industry-partnered clinical trials

Trials starting 2021 to 2025 in ClinicalTrials.gov in which a company and this university are the sponsor and a collaborator. Names are matched exactly, so a trial registered only under an affiliated hospital's own name is not counted here, and the count can be well below the university's real trial activity. Trials do not enter the score.

Examples:

  • NCT07407985 A Clinical Study to Evaluate GK01 Cell Injection in Combination With PD-1 Monoclonal Antibody for Advanced Solid Tumors with Beijing Geekgene Technology Co., LTD, 2025
  • NCT07201233 Clinical Study on the Safety and Efficacy of Umbilical Cord Blood Infusion in Treating Bone Marrow Suppression . with Shandong Qilu Stem Cells Engineering Co., Ltd., 2025
  • NCT07597759 Phase IIT Trial of SNA009 with SmartNuclide Biopharma, 2025
  • NCT07351903 A Single-arm, Open-label Study of GK01 in Combination With or Without Chemotherapy for the Adjuvant Treatment of Solid Tumors with Beijing Geekgene Technology Co., LTD, 2025
  • NCT07597772 Preliminary Trial of SNA014 for Pancreatic Cancer with SmartNuclide Biopharma, 2025
  • NCT07179783 Sacituzumab Tirumotecan in Combination With Tagitanlimab in the Treatment of Aggressive Variant Prostate Cancer (AVPC) and Neuroendocrine Prostate Cancer (NEPC) with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., 2025

Evidence checked

451 verified company links

Each counted link (one work, this university and one company) was confirmed against the affiliation text its author wrote; 577 of 1,028 candidate links were set aside.

Why links were set aside
  • 363 company name not written in the author's affiliation
  • 66 not an industry organisation
  • 44 ordinary-word name without a company suffix
  • 44 part of a university or public institute's own unit
  • 32 refresh_university_not_on_work
  • 9 a place or common word that failed its stricter rule
  • 19 for other reasons: smaller hand-audit findings, and links the current open record no longer supports

If a partner is missing or should not be here, send the evidence; corrections are free and reviewed against the public record.

GRP Partnership Intelligence Platform

Where Tianjin Medical University's collaboration could go next

This profile is free and public, and it stays that way. Beyond it, the GRP Partnership Intelligence Platform, a partner service arranged with each university, sets your record in both GRP indices beside the peers you choose: the universities and companies your peers work with that you do not, live funding calls matched to your strengths, the EU projects your peers have won, and a brief ready for your executive. It opens to partner universities on Monday 19 October 2026: enquire, and the GRP team will confirm availability and pricing for your university.

Request first access →  See what is inside →

The platform cannot move any university's position, band or score.

The other GRP index

Research Collaboration Index

In the Research Collaboration Index 2026, Tianjin Medical University ranks #753 of 1,195. It measures the whole research network, not only industry.

View the RCI profile →

Something wrong? Every figure comes from the public record and can be checked. If a partner is missing or should not be there, tell us and we will review it with the evidence. The 2027 edition will be calculated with the same published methodology. The window for universities to submit data for it is open now: submit data for the 2027 edition. The index is free, public and independent. No commercial relationship with any university or company changes any position, and no one can pay to be included, excluded or moved.